Stock IMRX IMMUNEERING CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News Immuneering Corporation

Equities

IMRX

US45254E1073

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
1.43 USD -4.67% Intraday chart for Immuneering Corporation -19.21% -80.54%
Apr. 09 Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting CI
Apr. 02 Mizuho Adjusts Price Target on Immuneering to $8 From $20 on Revised Revenue Assumptions for Lead Asset IMM-1-104, Keeps Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
GL
Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting
CI
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GL
Mizuho Adjusts Price Target on Immuneering to $8 From $20 on Revised Revenue Assumptions for Lead Asset IMM-1-104, Keeps Buy Rating
MT
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
GL
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
AQ
Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations
CI
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI
AQ
North American Morning Briefing : Investors -2-
DJ
Sector Update: Health Care Stocks Ease Late Afternoon
MT
Sector Update: Health Care
MT
Immuneering Shares Decline After Analysts Downgrades, Phase 1 Cancer Therapy Data
MT
Jefferies Downgrades Immuneering to Hold From Buy, Cuts Price Target to $3 From $16
MT
Needham Adjusts Price Target on Immuneering to $15 From $20, Maintains Buy Rating
MT
Chardan Lowers Price Target on Immuneering to $16 From $21, Keeps Buy Rating
MT
North American Morning Briefing : Inflation -2-
DJ
Guggenheim Downgrades Immuneering to Neutral From Buy
MT
TD Cowen Downgrades Immuneering to Market Perform From Outperform
MT
Transcript : Immuneering Corporation - Special Call
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMRX Stock
  4. News Immuneering Corporation